NCT06318442View on ClinicalTrials.gov

The GAPSID Study - How GLP-1 Analogues Prevent Steroid-Induced Diabetes

NARecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 15, 2024

Primary Completion Date

June 1, 2027

Study Completion Date

June 1, 2027

Conditions
Steroid-Induced DiabetesSteroid Induced Hyperglycemia
Interventions
DRUG

Semaglutide Oral Product

Oral semaglutide 3mg once uptitrated to twice daily

DRUG

Metformin Oral Tablet

Metformin modified release tablets 500mg once daily uptitrated to twice daily).

DRUG

Placebo

Placebo tablets

Trial Locations (1)

Unknown

RECRUITING

Imperial College Healthcare NHS Trust, London

All Listed Sponsors
lead

Imperial College London

OTHER